Company intelligence
CatalYm GmbH
Developing innovative immunotherapies to transform cancer patients’ lives by engaging their own immune systems.
Biotechnology Research
Martinsried, DE
51–200 employees
2 public signals
Verified activity
Signals from CatalYm GmbH
2 published signals
Presence & Recognition
CatalYm GmbH is attending the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer in Seoul, Republic of Korea from September 12-15.
Reported by CatalYm GmbH
Presence & Recognition
CatalYm GmbH CEO Scott Clarke is presenting at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 8, 2026, at 3:45 pm EDT at the Encore Boston Harbor.
Reported by CatalYm GmbH